[Form 3] ATAI Life Sciences N.V. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Ryan Barrett, identified as a Director and as the company’s Chief Legal and Business Officer in the remarks, filed an initial Form 3 for ATAI Life Sciences N.V. (ATAI) reporting direct ownership of 155,066 common shares and multiple fully or partially vested stock options. The filing lists nine option grants covering 347,000 to 757,915 underlying shares with exercise prices ranging from $1.18 to $15.00 and various exercisable/expiration dates through 03/03/2035.

Positive

• Direct ownership of 155,066 common shares by the Chief Legal and Business Officer
• Extensive option holdings totaling 2,918,711 underlying shares across nine grants (exercise prices from $1.18 to $15.00)
• Vesting schedules disclosed for each option grant, showing staged alignment over multiple years

Negative

• None.

Insights

Corporate Governance Specialist

Initial insider holding shows executive equity alignment with ATAI.

The Form 3 documents that Ryan Barrett directly owns 155,066 common shares and holds multiple stock options totaling 2,918,711 underlying shares across nine grants, with exercise prices from $1.18 to $15.00.

This disclosure identifies Barrett as a company officer and confirms standard Section 16 reporting; the mix of shares and long‑dated options is typical for senior executives and shows potential future dilution if exercised.

Compensation & Equity Analyst

Option vesting schedules indicate staged compensation over multi‑year periods.

The filing details vesting patterns: several grants vested 25% on specified dates (e.g., 01/01/2023, 09/01/2023, 03/14/2024, 01/01/2025) with remaining shares vesting monthly over 36 months, and one grant scheduled to begin vesting on 01/01/2026.

These schedules clarify when shares may become exercisable and potentially impact share count if exercised; no cash values or realization events are disclosed.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Barrett Christopher Ryan Cave

(Last) (First) (Middle)

C/O ATAI LIFE SCIENCES N.V.

PROF. J.H. BAVINCKLAAN 7

(Street)

AMSTERDAM P7 1183AT

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/01/2025

3. Issuer Name and Ticker or Trading Symbol
ATAI Life Sciences N.V. [ ATAI ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares	155,066	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	(1)	08/20/2030	Common Shares	347,000	$2.44	D
Stock Option	(1)	08/20/2030	Common Shares	284,832	$5.68	D
Stock Option	(1)	08/20/2030	Common Shares	53,680	$11.71	D
Stock Option	(1)	07/17/2031	Common Shares	221,764	$15	D
Stock Option	(2)	02/10/2032	Common Shares	231,900	$5.54	D
Stock Option	(3)	10/21/2032	Common Shares	71,620	$2.86	D
Stock Option	(4)	03/14/2033	Common Shares	400,000	$1.18	D
Stock Option	(5)	03/13/2034	Common Shares	550,000	$1.84	D
Stock Option	(6)	03/03/2035	Common Shares	757,915	$1.5	D

Explanation of Responses:

1. The stock option is fully vested.

2. The stock option vested as to 25% of the underlying shares on January 1, 2023, with the remaining underlying shares vesting in 36 substantially equal monthly installments thereafter.

3. The stock option vested as to 25% of the underlying shares on September 1, 2023, with the remaining underlying shares vesting in 36 substantially equal monthly installments thereafter.

4. The stock option vested as to 25% of the underlying shares on March 14, 2024, with the remaining underlying shares vesting in 36 substantially equal monthly installments thereafter.

5. The stock option vested as to 25% of the underlying shares on January 1, 2025, with the remaining underlying shares vesting in 36 substantially equal monthly installments thereafter.

6. The stock option shall vest as to 25% on January 1, 2026, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

Remarks:

Chief Legal and Business Officer Exhibit 24 - Power of Attorney.

	/s/ Ryan Barrett	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Ryan Barrett report on the ATAI Form 3?

The filing reports direct ownership of 155,066 common shares and nine stock option grants covering 2,918,711 underlying shares with exercise prices between $1.18 and $15.00.

Does the Form 3 disclose vesting schedules for Barrett’s options?

Yes. Several grants vested 25% on dates such as 01/01/2023, 09/01/2023, 03/14/2024, and 01/01/2025, with remaining shares vesting monthly over 36 months; one grant begins vesting on 01/01/2026.

What are the latest exercisable or expiration dates listed?

The listed derivative expirations extend through at least 03/03/2035, with exercisable dates shown beginning as early as 08/20/2030 for some grants.

What title does the reporting person hold at ATAI?

The remarks state the reporting person is the company’s Chief Legal and Business Officer and is also a Director.

Are the stock options fully vested?

The filing explains which options are fully vested and which follow 25% initial vesting followed by 36 monthly installments; one grant will start vesting on 01/01/2026.